白细胞介素-10家族抗肝纤维化的作用机制及临床应用价值

罗琪; 曾碧雨; 张荣; 黄良江; 付蕾; 姚春

doi:10.12449/JCH250422

白细胞介素-10家族抗肝纤维化的作用机制及临床应用价值

DOI: 10.12449/JCH250422

罗琪¹,
曾碧雨¹,
张荣¹,
黄良江²,
付蕾³,
姚春^1, , ,

1.
广西中医药大学研究生院，南宁 530200
2.
广西中医药大学第一附属医院肝病科，南宁 530200
3.
广西中医药大学科技部，南宁 530200

基金项目:

广西重点研发计划项目 (GuiKe AB22035076);

第七批全国老中医药专家学术经验继承工作项目 (GZY2024002);

2023年广西中医药多学科交叉创新团队 (GZKJ2301);

广西中医药大学“桂派中医药传承创新团队”A类资助项目 (2022A001);

广西中医药通阳散结法重点研究室项目 ;

国家中医药管理局高水平中医药重点学科建设项目-中医内科学 (zyyzdxk-2023166)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：付蕾、张荣负责设计研究思路；罗琪、曾碧雨负责查阅相关文献，资料归纳、分析，撰写论文；黄良江负责修改论文；姚春负责指导、审阅论文及最后定稿。

详细信息

通信作者:
姚春， yaochun111@163.com （ORCID： 0000-0003-2903-8814）

计量
- 文章访问数: 109
- HTML全文浏览量: 46
- PDF下载量: 12
- 被引次数: 0
出版历程
- 收稿日期: 2024-08-21
- 录用日期: 2024-09-26
- 出版日期: 2025-04-25

The mechanism and clinical application value of interleukin-10 family in anti-hepatic fibrosis

1.
Graduate School of Guangxi University of Chinese Medicine，Nanning 530200，China
2.
Department of Hepatology，The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530200，China
3.
Department of Science and Technology，Guangxi University of Chinese Medicine，Nanning 530200，China

Research funding:

Guangxi Key Research and Development Programme Project (GuiKe AB22035076);

the Seventh Batch of National Old Chinese Medicine Experts Academic Experience Inheritance Work Project (GZY2024002);

2023 Guangxi Chinese Medicine Multidisciplinary Cross-Innovation Team (GZKJ2301);

Guangxi University of Traditional Chinese Medicine ‘Gui school of traditional Chinese Medicine Inheritance and Innovation Team’ Class a Funding Project (2022A001);

Guangxi Key Research Laboratory Project of Traditional Chinese Medicine Tong Yang Dispersal Method ;

State Administration of Traditional Chinese Medicine High-level Key Discipline Construction Program of Traditional Chinese Medicine-Internal Medicine of Traditional Chinese Medicine (zyyzdxk-2023166)

More Information

Corresponding author: YAO Chun， yaochun111@163.com （ORCID： 0000-0003-2903-8814）

摘要

摘要: 白细胞介素-10（IL-10）家族在多种细胞中表达，具有广泛的生物学功能，在肝纤维化的发生发展中发挥重要作用。肝纤维化是一种慢性肝病，其特征是肝组织损伤后的异常修复、肝星状细胞活化及细胞外基质过度积累。IL-10家族成员包括IL-10、IL-19、IL-20、IL-22、IL-24、IL-26、IL-28、IL-29、IL-35等，在结构和功能上具有相似性，其表达水平的变化与肝纤维化的发展密切相关。适度上调IL-10家族成员表达可维持肝星状细胞静止状态，促进巨噬细胞向抗炎表型转化，调节自然杀伤细胞活性，进而抑制炎症反应，调控细胞凋亡和自噬，最终逆转肝纤维化进程。本文总结探讨了IL-10家族在抗肝纤维化中的作用机制及其在相关中西医治疗中的应用价值，为肝纤维化治疗提供新的思考。
- 肝纤维化 /
- 白细胞介素10 /
- 中西医结合
Abstract: The interleukin-10 （IL-10） family is expressed in various types of cells and has a wide range of biological functions， and it plays an important role in the development and progression of hepatic fibrosis. Hepatic fibrosis is a chronic liver disease characterized by abnormal repair of hepatic tissues after injury， activation of hepatic stellate cells， and excessive accumulation of extracellular matrix. The IL-10 family members include IL-10， IL-19， IL-20， IL-22， IL-24， IL-26， IL-28， IL-29， and IL-35， with similarities in structure and function， and changes in their expression levels are closely associated with the progression of hepatic fibrosis. Moderate upregulation of the expression of IL-10 family members can help maintain the quiescent state of hepatic stellate cells， promote the transformation of macrophages to anti-inflammatory phenotype， and regulate the activity of natural killer cells， thereby inhibiting inflammatory response， regulating cell apoptosis and autophagy， and finally reversing the progression of hepatic fibrosis. This article discusses the mechanism of action of IL-10 family members and their application in traditional Chinese medicine and Western medicine therapies， in order to provide new thoughts for the treatment of hepatic fibrosis.
- Hepatic Fibrosis /
- Interleukin-10 /
- Integrated Traditional Chinese Medicine & Western Medicine

HTML全文

参考文献(55)

[1]	GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability(YLDs), disability-adjusted life-years(DALYs), and healthy life expectancy(HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403( 10440): 2133- 2161. DOI: 10.1016/S0140-6736(24)00757-8.
[2]	GILGENKRANTZ H, MALLAT A, MOREAU R, et al. Targeting cell-intrinsic metabolism for antifibrotic therapy[J]. J Hepatol, 2021, 74( 6): 1442- 1454. DOI: 10.1016/j.jhep.2021.02.012.
[3]	STEEN EH, WANG XY, BALAJI S, et al. The role of the anti-inflammatory cytokine interleukin-10 in tissue fibrosis[J]. Adv Wound Care(New Rochelle), 2020, 9( 4): 184- 198. DOI: 10.1089/wound.2019.1032.
[4]	WEI HX, LI BF, SUN AY, et al. Interleukin-10 family cytokines immunobiology and structure[J]. Adv Exp Med Biol, 2019, 1172: 79- 96. DOI: 10.1007/978-981-13-9367-9_4.
[5]	WANG XT, WONG K, OUYANG WJ, et al. Targeting IL-10 family cytokines for the treatment of human diseases[J]. Cold Spring Harb Perspect Biol, 2019, 11( 2): a028548. DOI: 10.1101/cshperspect.a028548.
[6]	de BRITO RJVC, CARMO RF DO, SILVA BMS, et al. Liver expression of IL-22, IL-22R1 and IL-22BP in patients with chronic hepatitis C with different fibrosis stages[J]. Cytokine, 2022, 150: 155784. DOI: 10.1016/j.cyto.2021.155784.
[7]	NGA HT, MOON JS, TIAN JW, et al. Interleukin-10 attenuates liver fibrosis exacerbated by thermoneutrality[J]. Front Med(Lausanne), 2021, 8: 672658. DOI: 10.3389/fmed.2021.672658.
[8]	ZHENG MH, FANG WZ, YU ML, et al. IL-6 and IL-10 gene polymorphisms and cirrhosis of liver risk from a comprehensive analysis[J]. BMC Endocr Disord, 2021, 21( 1): 242. DOI: 10.1186/s12902-021-00906-3.
[9]	LIU QH, YANG QL, WU ZF, et al. IL-1β-activated mTORC2 promotes accumulation of IFN-γ⁺ γδ T cells by upregulating CXCR3 to restrict hepatic fibrosis[J]. Cell Death Dis, 2022, 13( 4): 289. DOI: 10.1038/s41419-022-04739-3.
[10]	ROEHLEN N, CROUCHET E, BAUMERT TF. Liver fibrosis: Mechanistic concepts and therapeutic perspectives[J]. Cells, 2020, 9( 4): 875. DOI: 10.3390/cells9040875.
[11]	ZHANG XT, ZENG Y, ZHAO LY, et al. Targeting hepatic stellate cell death to reverse hepatic fibrosis[J]. Curr Drug Targets, 2023, 24( 7): 568- 583. DOI: 10.2174/1389450124666230330135834.
[12]	JIANG Y, XIANG C, ZHONG F, et al. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis[J]. Theranostics, 2021, 11( 1): 361- 378. DOI: 10.7150/thno.46360.
[13]	XU Y, LIU F, HE D, et al. Monocyte-derived immature dendritic cells negatively regulate hepatic stellate cells in vitro by secreting IL-10[J]. Immunobiology, 2023, 228( 2): 152315. DOI: 10.1016/j.imbio.2022.152315.
[14]	WANG HH, HUANG JH, SUE MH, et al. Interleukin-24 protects against liver injury in mouse models[J]. EBioMedicine, 2021, 64: 103213. DOI: 10.1016/j.ebiom.2021.103213.
[15]	ZHANG XQ, XIE XY, WANG YZ, et al. Interleukin-26 promotes the proliferation and activation of hepatic stellate cells to exacerbate liver fibrosis by the TGF-β1/Smad2 signaling pathway[J]. Int J Clin Exp Pathol, 2019, 12( 12): 4271- 4279.
[16]	JAIN I, BROUGHAM-COOK A, UNDERHILL GH. Effect of distinct ECM microenvironments on the genome-wide chromatin accessibility and gene expression responses of hepatic stellate cells[J]. Acta Biomater, 2023, 167: 278- 292. DOI: 10.1016/j.actbio.2023.06.018.
[17]	LUCANTONI F, MARTÍNEZ-CEREZUELA A, GRUEVSKA A, et al. Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis: Are we there yet?[J]. J Pathol, 2021, 254( 3): 216- 228. DOI: 10.1002/path.5678.
[18]	ZHENG B, GAO ZY, LIANG LM, et al. Autophagy of hepatic stellate cell induced by Clonorchis sinensis[J]. Mol Biol Rep, 2022, 49( 3): 1895- 1902. DOI: 10.1007/s11033-021-07001-9.
[19]	PENG XQ, YANG HX, TAO LJ, et al. Fluorofenidone alleviates liver fibrosis by inhibiting hepatic stellate cell autophagy via the TGF-β1/Smad pathway: Implications for liver cancer[J]. PeerJ, 2023, 11: e16060. DOI: 10.7717/peerj.16060.
[20]	MENG YX, ZHAO R, HUO LJ. Interleukin-22 alleviates alcohol-associated hepatic fibrosis, inhibits autophagy, and suppresses the PI3K/AKT/mTOR pathway in mice[J]. Alcohol Clin Exp Res(Hoboken), 2023, 47( 3): 448- 458. DOI: 10.1111/acer.15021.
[21]	CHEN JB, GUO QL, CHEN QD, et al. Interleukin 10 inhibits oxidative stress-induced autophagosome formation in hepatic stellate cells by activating the mTOR-STAT3 pathway[J]. Exp Cell Res, 2022, 411( 2): 113001. DOI: 10.1016/j.yexcr.2021.113001.
[22]	CHEN DM, CHEN JB, CHEN YZ, et al. Interleukin-10 regulates starvation-induced autophagy through the STAT3-mTOR-p70s6k axis in hepatic stellate cells[J]. Exp Biol Med(Maywood), 2022, 247( 10): 832- 841. DOI: 10.1177/15353702221080435.
[23]	ZHANG MF, SERNA-SALAS S, DAMBA T, et al. Hepatic stellate cell senescence in liver fibrosis: Characteristics, mechanisms and perspectives[J]. Mech Ageing Dev, 2021, 199: 111572. DOI: 10.1016/j.mad.2021.111572.
[24]	GUO QL, CHEN MH, CHEN QD, et al. Silencing p53 inhibits interleukin 10-induced activated hepatic stellate cell senescence and fibrotic degradation in vivo[J]. Exp Biol Med(Maywood), 2021, 246( 4): 447- 458. DOI: 10.1177/1535370220960391.
[25]	HUANG YH, CHEN MH, GUO QL, et al. Interleukin-10 induces senescence of activated hepatic stellate cells via STAT3-p53 pathway to attenuate liver fibrosis[J]. Cell Signal, 2020, 66: 109445. DOI: 10.1016/j.cellsig.2019.109445.
[26]	WANG C, MA C, GONG LH, et al. Macrophage polarization and its role in liver disease[J]. Front Immunol, 2021, 12: 803037. DOI: 10.3389/fimmu.2021.803037.
[27]	WANG Z, DU KL, JIN NK, et al. Macrophage in liver fibrosis: Identities and mechanisms[J]. Int Immunopharmacol, 2023, 120: 110357. DOI: 10.1016/j.intimp.2023.110357.
[28]	CHONG SG, CHEN G, DANG ZS, et al. Echinococcus multilocularis drives the polarization of macrophages by regulating the RhoA-MAPK signaling pathway and thus affects liver fibrosis[J]. Bioengineered, 2022, 13( 4): 8747- 8758. DOI: 10.1080/21655979.2022.2056690.
[29]	SU SB, QIN SY, XIAN XL, et al. Interleukin-22 regulating Kupffer cell polarization through STAT3/Erk/Akt crosstalk pathways to extenuate liver fibrosis[J]. Life Sci, 2021, 264: 118677. DOI: 10.1016/j.lfs.2020.118677.
[30]	YUAN W, WANG BY, YANG L, et al. The antifibrotic role of natural killer cells in liver fibrosis[J]. Exp Biol Med(Maywood), 2022, 247( 14): 1235- 1243. DOI: 10.1177/15353702221092672.
[31]	MARTÍNEZ-CHANTAR ML, DELGADO TC, BERAZA N. Revisiting the role of natural killer cells in non-alcoholic fatty liver disease[J]. Front Immunol, 2021, 12: 640869. DOI: 10.3389/fimmu.2021.640869.
[32]	ALI AK, KOMAL AK, ALMUTAIRI SM, et al. Natural killer cell-derived IL-10 prevents liver damage during sustained murine cytomegalovirus infection[J]. Front Immunol, 2019, 10: 2688. DOI: 10.3389/fimmu.2019.02688.
[33]	FAN YT, ZHANG WD, WEI HM, et al. Hepatic NK cells attenuate fibrosis progression of non-alcoholic steatohepatitis in dependent of CXCL10-mediated recruitment[J]. Liver Int, 2020, 40( 3): 598- 608. DOI: 10.1111/liv.14307.
[34]	HU Y, WANG XL, WEI YH, et al. Functional inhibition of natural killer cells in a BALB/c mouse model of liver fibrosis induced by Schistosoma japonicum infection[J]. Front Cell Infect Microbiol, 2020, 10: 598987. DOI: 10.3389/fcimb.2020.598987.
[35]	YU B, QIN SY, HU BL, et al. Resveratrol improves CCl₄-induced liver fibrosis in mouse by upregulating endogenous IL-10 to reprogramme macrophages phenotype from M(LPS) to M(IL-4)[J]. Biomed Pharmacother, 2019, 117: 109110. DOI: 10.1016/j.biopha.2019.109110.
[36]	WANG KP, WANG JF, SONG MZ, et al. Angelica sinensis polysaccharide attenuates CCl₄-induced liver fibrosis via the IL-22/STAT3 pathway[J]. Int J Biol Macromol, 2020, 162: 273- 283. DOI: 10.1016/j.ijbiomac.2020.06.166.
[37]	ZHOU X, LI XT, YI KF, et al. Magnesium isoglycyrrhizinate ameliorates lipopolysaccharide-induced liver injury by upregulating autophagy and inhibiting inflammation via IL-22 expression[J]. Bioorg Chem, 2022, 128: 106034. DOI: 10.1016/j.bioorg.2022.106034.
[38]	ZHOU X, YU L, ZHOU M, et al. Dihydromyricetin ameliorates liver fibrosis via inhibition of hepatic stellate cells by inducing autophagy and natural killer cell-mediated killing effect[J]. Nutr Metab(Lond), 2021, 18( 1): 64. DOI: 10.1186/s12986-021-00589-6.
[39]	GUO MM, WANG ZD, DAI JY, et al. Glycyrrhizic acid alleviates liver fibrosis in vitro and in vivo via activating CUGBP1-mediated IFN-γ/STAT1/Smad7 pathway[J]. Phytomedicine, 2023, 112: 154587. DOI: 10.1016/j.phymed.2022.154587.
[40]	ABO-ZAID MA, SHAHEEN ES, ISMAIL AH. Immunomodulatory effect of curcumin on hepatic cirrhosis in experimental rats[J]. J Food Biochem, 2020, 44( 6): e13219. DOI: 10.1111/jfbc.13219.
[41]	BAI JJ, QIAN BL, CAI TY, et al. Aloin attenuates oxidative stress, inflammation, and CCl₄-induced liver fibrosis in mice: Possible role of TGF-β/smad signaling[J]. J Agric Food Chem, 2023, 71( 49): 19475- 19487. DOI: 10.1021/acs.jafc.3c01721.
[42]	MAI ZH, HUANG Y, HUANG D, et al. Reversine and herbal Xiang-Sha-Liu-Jun-Zi decoction ameliorate thioacetamide-induced hepatic injury by regulating the RelA/NF-κB/caspase signaling pathway[J]. Open Life Sci, 2020, 15( 1): 696- 710. DOI: 10.1515/biol-2020-0059.
[43]	ZHENG YF, JI SX, LI X, et al. Qijia Rougan formula ameliorates ECM deposition in hepatic fibrosis by regulating the JAK1/STAT6-microRNA-23a feedback loop in macrophage M2 polarization[J]. Biomed Pharmacother, 2023, 168: 115794. DOI: 10.1016/j.biopha.2023.115794.
[44]	WANG FC, GAN J, LI R, et al. Naringin from Ganshuang granule inhibits inflammatory to relieve liver fibrosis through TGF-β-Smad signaling pathway[J]. PLoS One, 2024, 19( 6): e0304185. DOI: 10.1371/journal.pone.0304185.
[45]	LEI W, ZHAO CC, SUN JS, et al. Electroacupuncture ameliorates intestinal barrier destruction in mice with bile duct ligation-induced liver injury by activating the cholinergic anti-inflammatory pathway[J]. Neuromodulation, 2022, 25( 8): 1122- 1133. DOI: 10.1016/j.neurom.2022.02.001.
[46]	CHOI JS, JEONG IS, HAN JH, et al. IL-10-secreting human MSCs generated by TALEN gene editing ameliorate liver fibrosis through enhanced anti-fibrotic activity[J]. Biomater Sci, 2019, 7( 3): 1078- 1087. DOI: 10.1039/c8bm01347k.
[47]	GOU YN, WENG YG, CHEN Q, et al. Carboxymethyl chitosan prolongs adenovirus-mediated expression of IL-10 and ameliorates hepatic fibrosis in a mouse model[J]. Bioeng Transl Med, 2022, 7( 3): e10306. DOI: 10.1002/btm2.10306.
[48]	SUNGKAR T, PUTRA A, LINDARTO D, et al. Intravenous umbilical cord-derived mesenchymal stem cells transplantation regulates hyaluronic acid and interleukin-10 secretion producing low-grade liver fibrosis in experimental rat[J]. Med Arch, 2020, 74( 3): 177- 182. DOI: 10.5455/medarh.2020.74.177-182.
[49]	CHOI JS, JEONG IS, PARK YJ, et al. HGF and IL-10 expressing ALB::GFP reporter cells generated from iPSCs show robust anti-fibrotic property in acute fibrotic liver model[J]. Stem Cell Res Ther, 2020, 11( 1): 332. DOI: 10.1186/s13287-020-01745-0.
[50]	ZHANG HC, HAN KY, LI H, et al. hPMSCs regulate the level of TNF-α and IL-10 in Th1 cells and improve hepatic injury in a GVHD mouse model via CD73/ADO/Fyn/Nrf2 axis[J]. Inflammation, 2024, 47( 1): 244- 263. DOI: 10.1007/s10753-023-01907-1.
[51]	WANG QL, KIM SY, MATSUSHITA H, et al. Oral administration of PEGylated TLR7 ligand ameliorates alcohol-associated liver disease via the induction of IL-22[J]. Proc Natl Acad Sci USA, 2021, 118( 1): e2020868118. DOI: 10.1073/pnas.2020868118.
[52]	LI SW, TAKAHARA T, QUE WT, et al. Hydrogen-rich water protects against liver injury in nonalcoholic steatohepatitis through HO-1 enhancement via IL-10 and Sirt 1 signaling[J]. Am J Physiol Gastrointest Liver Physiol, 2021, 320( 4): G450- G463. DOI: 10.1152/ajpgi.00158.2020.
[53]	AL-NAJJAR AH, AYOB AR, AWAD AS. Role of lactoferrin in treatment of bile duct ligation-induced hepatic fibrosis in rats: Impact on inflammation and TGF-β1/Smad2/α SMA signaling pathway[J]. J Clin Exp Hepatol, 2023, 13( 3): 428- 436. DOI: 10.1016/j.jceh.2022.12.014.
[54]	KABIRI-ARANI S, MOTALLEBI M, TAHERI MA, et al. The effect of heat-killed Lactobacillus plantarum on oxidative stress and liver damage in rats with bile duct ligation-induced hepatic fibrosis[J]. Probiotics Antimicrob Proteins, 2024, 16( 1): 196- 211. DOI: 10.1007/s12602-022-10033-7.
[55]	ABU-RISHA SE, SOKAR SS, ELBOHOTY HR, et al. Combined carvacrol and cilostazol ameliorate ethanol-induced liver fibrosis in rats: Possible role of SIRT1/Nrf2/HO-1 pathway[J]. Int Immunopharmacol, 2023, 116: 109750. DOI: 10.1016/j.intimp.2023.109750.